SirPAD Subgroup Trial Results Will Debut at VIVA 2026
New data from a trial of sirolimus-coated balloons for arterial disease will be presented in Las Vegas this October.
Updated on Sept. 21, 2026 in Stroke
Researchers will present fresh subgroup findings from the SirPAD trial at the VIVA 2026 conference, taking place from October 3-6 in Las Vegas. The presentation will focus on 597 patients treated for femoropopliteal peripheral artery disease.
Why it matters
The analysis offers deeper insight into revascularization outcomes for patients who do not have tissue loss, building on the main trial's demonstration of reduced adverse limb events.
The SirPAD trial randomized 1,252 patients with symptomatic infrainguinal PAD to compare MagicTouch sirolimus-coated balloons with uncoated balloons. The ongoing study previously reported a significant reduction in major adverse limb events over a 1-year follow-up period.
The players
Prof. Dr. Stefano Barco
He is the researcher responsible for presenting the new subgroup analysis results at the VIVA 2026 conference.
VIVA 2026
This is a prominent vascular medical conference held at the Bellagio Las Vegas that serves as a venue for new clinical trial disclosures.
The details
Prof. Dr. Stefano Barco is slated to reveal the new data during the conference at the Bellagio Las Vegas. The analysis specifically targets the effectiveness of the balloon-based intervention in the femoropopliteal segment.
Timeline
September 21, 2026: Announcement of upcoming trial presentation.
October 3-6, 2026: VIVA 2026 conference in Las Vegas.
The Big Picture
This subgroup analysis follows the pattern set by the SirPAD trial, which evaluates the efficacy of drug-coated balloon technology in peripheral artery interventions. The research extends the initial trial conclusions by focusing on specific patient populations within the larger study.
Patients dealing with peripheral artery disease may see new treatment standards emerge based on the long-term success of sirolimus-coated balloons. These clinical updates help physicians determine the most durable revascularization options for symptomatic individuals.
The takeaway
Clinicians and patients should monitor the upcoming results to see if the reduction in adverse limb events remains consistent across specific arterial disease subgroups. This trial continues to shape how medical professionals evaluate angioplasty outcomes for chronic artery conditions.
Further reading
For broader information on vascular health and medical interventions, explore our section on Stroke.
More information
Find more details on the technology and trials at Concept Medical company information.
